The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

Moderna stock popped 11.7% to 47.53, while BioNTech shares 5.6% to 126.88. BioNTech stock is consolidating with a buy point at 131.49.

Moderna said it filed patents from 2010 to 2016 for its mRNA technology, which was critical in the company's creation of its own Covid vaccine. The company alleges that Pfizer and BioNTech then ...

BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA Approves Updated ...

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

On April 12, 2024, Judge Richard G. Stearns granted BioNTech and Pfizer’s motion to stay the district court litigation pending the resolution of IPR2023-01358 and IPR2023-01359.

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest, most ...